Novavax COVID-19 vaccine hits 90% efficacy in pivotal U.S. trial The top 10 highest paid biopharma R&D executives in 2020 J&J's Burton grabs hold of Moderna rocket ship as the vaccine developer’s next chief medical officer Sponsored: Inside Track: Behind the Scenes of a Major Biotech SPAC GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race Humanigen angling to go from zero to $1B with U.S., U.K. COVID-19 therapy filings Celltrion's COVID-19 antibody gets a phase 3 win as virus variants snare existing therapies Flagship Pioneering flags down another $2.2B to expand preemptive, pioneering medicine divisions HiFiBiO gets high-five from investors with $75M series D to bring two programs into clinic EHA: Epizyme's first-in-class multiple myeloma drug candidate inhibits tumors in mice Johnson & Johnson told to throw out 60M COVID-19 shots made at troubled Emergent site: report Here's why Abernethy wanted to jump on board at Verily and her ambitions to grow its research business Featured Story | By Nick Paul Taylor Novavax’s COVID-19 vaccine candidate has achieved 90.4% efficacy in the pivotal trial designed to support U.S. approval. The phase 3 data set Novavax up to file for approval in the third quarter. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus If you (like us) thought George Yancopoulous, M.D., Ph.D., would top this list, well, that would have been a pretty safe bet. What none of us predicted was just how big his lead would be. The Regeneron R&D chief raked in $134.3 million, a whopping 550% bump over his compensation the previous year. Yancopoulos' compensation eclipsed the pay of his peers on this list by at least $109 million. read more By Annalee Armstrong Moderna launched itself into the big leagues last year with its COVID-19 vaccine, and now it's poaching talent from the world’s biggest healthcare company. Paul Burton, M.D., Ph.D., will join the Cambridge, Massachusetts-based biotech as chief medical officer from Johnson & Johnson’s Janssen unit. read more Sponsored by: RBC Capital Markets Take a closer look at the SPAC phenomenon with Dr. David Hung, Founder and CEO of Nuvation Bio and Michelle Doig, Omega Funds Partner and President of its Omega Alpha SPAC. read more By Nick Paul Taylor GlaxoSmithKline is paying iTeos Therapeutics $625 million upfront for rights to phase 1 anti-TIGIT monoclonal antibody EOS-448. The deal sets GSK up to challenge Bristol Myers Squibb, Gilead, Merck and Roche for the red-hot corner of the immuno-oncology market. read more By Annalee Armstrong Humanigen could go from zero to $1 billion in sales if its COVID-19 treatment clears regulatory review in the U.S. and U.K., analysts from Cantor Fitzgerald said today. The self-described “cytokine storm company” filed a rolling submission in the U.K. Monday for lenzilumab in hospitalized COVID-19 patients. This follows a May 28 authorization request submitted to the FDA. read more By Amirah Al Idrus Chalk one up for COVID-19 antibodies: Celltrion’s prospect, regdanvimab, beat placebo at preventing hospitalization and death in patients with mild to moderate symptoms and helped those patients recover more quickly in a phase 3 study. The results arrive as the rise of SARS-CoV-2 variants raise concerns about existing antibody drugs, especially those given as single agents. read more By Kyle LaHucik Flagship Pioneering wanted a little more heft behind its latest voyage. The biotech innovator and venture firm increased its April 2020 fund from $1.1 billion to a total of $3.37 billion on Monday to drive a preemptive medicine focus. read more By Kyle LaHucik HiFiBiO has another $75 million to take two lead antibody oncology programs into the clinic and continue the phase 1 study of its COVID-19 antibody candidate. Mirae Asset Financial Group led the Series D round alongside half a dozen other new investors like B Capital Group. read more By Angus Liu Epizyme has reported positive data from mouse studies for a potential first-in-class multiple myeloma therapy. The drug, a small-molecule SETD2 inhibitor dubbed EPZ-719, significantly slowed tumor growth in mice, according to data presented at the European Hematology Association virtual congress. read more By Noah Higgins-Dunn The FDA has instructed Johnson & Johnson to toss about 60 million COVID-19 vaccines made at Emergent BioSolutions' troubled factory in Baltimore, Maryland, the New York Times reports. read more By Heather Landi Verily's recent hiring of former FDA official Amy Abernethy, M.D., Ph.D., signals it has strong ambitions to transform research to make it easier and faster to run clinical trials. Abernethy recently chatted with Fierce Healthcare about her move to the Alphabet life sciences venture and her vision to grow the company's clinical research business. read more | | LabConnect is the leader in innovative central laboratory services for cell and gene therapies. Far more than typical central laboratory support, only LabConnect offers comprehensive, specialized services customizable to meet the unique needs of your complex clinical trials. Connect with us today. |
Resources Sponsored by: Thermo Fisher Scientific Learn how the diagnostics industry is being fundamentally transformed with point-of-care molecular testing. Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 